Menu
← Oncology Approval Tracker
FDA DECISION ·
Stimufend
pegfilgrastim-fpgk · Fresenius Kabi
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Pegfilgrastim biosimilar for reducing infection manifested as febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy with a clinically significant risk.
LAMPGEN ANALYSIS
Why it matters
The product expands long-acting G-CSF supply options for eligible regimens.
What research teams should watch
Check presentation, traceability and chemotherapy-cycle timing when incorporating the product into supportive care orders.
PRIMARY RECORDS